Efficacy of prolonged-release fampridine <i>versus</i> placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE.

Ther Adv Neurol Disord · 2022 · PMC9121513 · PMID 35601756

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

18 In ENHANCE, the improvement in BBS observed with PR-fampridine versus placebo did not reach statistical significance. 20 One of the key advantages of this integrated pooled analysis is that sample size is increased, providing greater power in the evaluation of treatment differences.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.